BioClinica to Release Third Quarter 2012 Financial Results on November 8, 2012

-- Conference Call to be Held at 11:00 a.m. EST--

BioClinica to Release Third Quarter 2012 Financial Results on November 8, 2012

<0> Company:Jim Dorsey, 267-757-3040orInvestors:Cheryl Schneider, 212-564-4700orFinancial Media:Bill Gordon, 212-564-4700 </0>

BioClinica, Inc. (NASDAQ: BIOC), a leading global provider of clinical trial management solutions, will release its financial results for the third quarter ended September 30, 2012 on Thursday, November 8, 2012.

Management of BioClinica, Inc. will host a conference call on the same day at 11:00 a.m. EST. Those who wish to participate in the conference call may telephone 877-869-3847 from the U.S.; international callers may telephone 201-689-8261, approximately 15 minutes before the call. There will be a simultaneous webcast on . A digital replay will be available by telephone approximately two hours after the call’s completion for two weeks, and may be accessed by dialing 877-660-6853from the U.S. or 201-612-7415 for international callers, Conference ID #401423. The replay will also be on the website under the “Investors” section at for two weeks.

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit